Quarterly report pursuant to Section 13 or 15(d)

Schedule of Accounts Payable to Related Party (Details)

v3.24.2.u1
Schedule of Accounts Payable to Related Party (Details) - USD ($)
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Defined Benefit Plan Disclosure [Line Items]    
Beginning balance [1] $ 3,515,000  
Ending balance [1] 842,000  
Cytovance Biologics Inc [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Beginning balance 3,515,000 $ 2,283,000
Invoices, net 778,000 2,877,000
Payments in cash (2,641,000) (1,130,000)
Payments in common stock, at fair value (810,000) (1,120,000)
Ending balance $ 842,000 $ 2,910,000
[1] Accounts Payable to Cytovance Biologics, Inc., a Related Party